Clinical Trials for Mesothelioma Patients—A Study of Carboplatin, Bevacizumab and Pemetrexed for MPM Patients: Inclusion Criteria

Read about the inclusion criteria for a current clinical trial about the use of Carboplatin, Bevacizumab and Pemetrexed for MPM patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Patient must have histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM)
Patient must have MPM with measurable disease.
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Patient must have adequate renal function with a serum creatinine level of less than 1.5 mg/dl and patient should have a calculated creatinine clearance of more than 40ml/min.
Patient must have adequate hepatic function with a serum bilirubin level of less that 3mg/dl, and an alkaline phosphatase, ALT and AST of less than five times the upper limit of normal
Patient must also have evidence of adequate bone marrow function with an absolute neutrophil count of more than 1500 cells per deciliter and a platelet count of more than 100,000 per deciliter.
Patients must be more than 28 days since prior open biopsy; more than 7 days since prior fine-needle aspiration; more than 7 days since prior core biopsy; more than 28 days since prior surgery.
Patients must be able to take dexamethasone, folic acid, and vitamin B-12 supplementation.
All patients must sign informed consent that will detail the investigational nature of the study in accordance with the institutional and federal guidelines.
Patients with clinically significant pleural effusions or ascities (symptomatic or detectable by clinical exam) should have their effusions drained prior to enrollment on the clinical trial.

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.